Cabozantinib and Nivolumab With or Without Live Bacterial Supplementation for Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Nat. Med. 2024 Jun 28;[EPub Ahead of Print], H Ebrahimi, N Dizman, L Meza, J Malhotra, X Li, T Dorff, P Frankel, M Llamas-Quitiquit, J Hsu, ZB Zengin, M Alcantara, D Castro, B Mercier, N Chawla, A Chehrazi-Raffle, R Barragan-Carrillo, S Jaime-Casas, A Govindarajan, J Gillece, J Trent, PP Lee, TP Parks, M Takahashi, A Hayashi, M Kortylewski, JG Caporaso, K Lee, A Tripathi, SK PalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.